Mesolimbic dopamine super-sensitivity in melanin-concentrating hormone-1 receptor-deficient mice

Journal of Neuroscience

Volumn 25, Issue 4, 2005, Pages 914-922

  Smith, Daniel G ^a   Tzavara, Eleni T ^a   Shaw, Janice ^a   Luecke, Susan ^a   Wade, Mark ^a   Davis, Richard ^a   Salhoff, Craig ^a   Nomikos, George G ^a   Gehlert, Donald R ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Dopamine; Hyperactivity; Knock out mice; Melanin concentrating hormone 1 receptor; Mesolimbic; Norepinephrine; Nucleus accumbens

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; BRAIN MONOAMINE; DEXAMPHETAMINE; DOPAMINE; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; MELANIN CONCENTRATING HORMONE; MELANIN CONCENTRATING HORMONE 1 RECEPTOR; NORADRENALIN; NORADRENALIN TRANSPORTER; QUINPIROLE; SEROTONIN; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CAUDATE NUCLEUS; CONTROLLED STUDY; GENOTYPE; GLOBUS PALLIDUS; LIMBIC CORTEX; MALE; MESOLIMBIC DOPAMINERGIC SYSTEM; MICRODIALYSIS; MOUSE; MOUSE STRAIN; NONHUMAN; OLFACTORY BULB; PRIORITY JOURNAL; PUTAMEN; RECEPTOR BINDING; UPREGULATION; VENTRAL TEGMENTUM; WILD TYPE;

2,3,4,5-TETRAHYDRO-7,8-DIHYDROXY-1-PHENYL-1H-3-BENZAZEPINE; ANIMALS; DEXTROAMPHETAMINE; DOPAMINE; DOPAMINE AGONISTS; LIMBIC SYSTEM; MALE; MEMBRANE TRANSPORT PROTEINS; MESENCEPHALON; MICE; MICE, KNOCKOUT; MOTOR ACTIVITY; NEURAL PATHWAYS; NOREPINEPHRINE; NUCLEUS ACCUMBENS; QUINPIROLE; RECEPTORS, DOPAMINE; RECEPTORS, SOMATOSTATIN; SEROTONIN;

EID: 12844265880     PISSN: 02706474     EISSN: None     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.4079-04.2005     Document Type: Article

References (68)

1. Amara SG, Kuhar MJ (1993) Neurotransmitter transporters: recent progress. Annu Rev Neurosci 16:73-93.
2. An S, Cutler G, Zhao JJ, Huang SG, Tian H, Li W, Liang L, Rich M, Bakleh A, Du J, Chen JL, Dai K (2001) Identification and characterization of a melanin-concentrating hormone receptor. Proc Natl Acad Sci USA 98:7576-7581.
3. Bittencourt JC, Presse F, Arias C, Peto C, Vaughan J, Nahon JL, Vale W, Sawchenko PE (1992) The melanin-concentrating hormone system of the rat brain: an immuno- and hybridization histochemical characterization. J Comp Neurol 319:218-245.
4. Borowsky B, Durkin MM, Ogozalek K, Marzabadi MR, DeLeon J, Lagu B, Heurich R, Lichtblau H, Shaposhnik Z, Daniewska I, Blackburn TP, Branchek TA, Gerald C, Vaysse PJ, Forray C (2002) Antidepressant, anxiolytic and anorectic effects of a melanin-concentrating hormone-1 receptor antagonist. Nat Med 8:825-830.
5. Bothe GW, Bolivar VJ, Vedder MJ, Geistfeld JG (2004) Genetic and behavioral differences among five inbred mouse strains commonly used in the production of transgenic and knockout mice. Genes Brain Behav 3:149-157.
6. Chambers J, Ames RS, Bergsma D, Muir A, Fitzgerald LR, Hervieu G, Dytko GM, Foley JJ, Martin J, Liu WS, Park J, Ellis C, Ganguly S, Konchar S, Cluderay J, Leslie R, Wilson S, Sarau HM (1999) Melanin-concentrating hormone is the cognate ligand for the orphan G-protein-coupled receptor SLC-1. Nature 400:261-265.
7. Chefer VI, Kieffer BL, Shippenberg TS (2003) Basal and morphine-evoked dopaminergic neurotransmission in the nucleus accumbens of MOR- and DOR-knockout mice. Eur J Neurosci 18:1915-1922.
8. Chen Y, Hu C, Hsu CK, Zhang Q, Bi C, Asnicar M, Hsiung HM, Fox N, Slieker LJ, Yang DD, Heiman ML, Shi Y (2002) Targeted disruption of the melanin-concentrating hormone receptor-1 results in hyperphagia and resistance to diet-induced obesity. Endocrinology 143:2469-2477.
9. Crawley JN, Belknap JK, Collins A, Crabbe JC, Frankel W, Henderson N, Hitzemann RJ, Maxson SC, Miner LL, Silva AJ, Wehner JM, Wynshaw-Boris A, Paylor R (1997) Behavioral phenotypes of inbred mouse strains: implications and recommendations for molecular studies. Psychopharmacology (Berl) 132:107-124.
10. Dawson TM, Gehlert DR, McCabe RT, Barnett A, Wamsley JK (1986) D-1 dopamine receptors in the rat brain: a quantitative autoradiographic analysis. J Neurosci 6:2352-2365.
11. DiLeone RJ, Georgescu D, Nestler EJ (2003) Lateral hypothalamic neuropeptides in reward and drug addiction. Life Sci 73:759-768.
12. 2 dopamine receptors in mediating locomotor activity elicited from the nucleus accumbens of rats. Brain Res 487:267-277.
13. File SE, Seth P (2003) A review of 25 years of the social interaction test. Eur J Pharmacol 463:35-53.
14. Fink JS, Smith GP (1980) Mesolimbicocortical dopamine terminal fields are necessary for normal locomotor and investigatory exploration in rats. Brain Res 199:359-384.
15. Franklin KBJ, Paxinos G (1997) The mouse brain in stereotaxic coordinates. San Diego: Academic.
16. Frantz KJ, Van Hartesveldt C (1995) Sulpiride antagonizes the biphasic locomotor effects of quinpirole in weanling rats. Psychopharmacology (Berl) 119:299-304.
17. Gehlert DR, Schoepp DD (1992) Striatal quinolinic acid lesions increase [3H] WIN 35,428 binding to the dopamine transporter. Neurochem Int 21:581-584.
18. Gehlert DR, Schober DA, Gackenheimer SL (1995) Comparison of (R)-[3H]tomoxetine and (R/S)-[3H]nisoxetine binding in rat brain. J Neurochem 64:2792-2800.
19. Gerber DJ, Sotnikova TD, Gainetdinov RR, Huang SY, Caron MG, Tonegawa S (2001) Hyperactivity, elevated dopaminergic transmission, and response to amphetamine in M1 muscarinic acetylcholine receptor-deficient mice. Proc Natl Acad Sci USA 98:15312-15317.
20. Giros B, Jaber M, Jones SR, Wightman RM, Caron MG (1996) Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379:606-612.
21. Graybiel AM, Moratalla R, Robertson HA (1990) Amphetamine and cocaine induce drug-specific activation of the c-fos gene in striosome-matrix compartments and limbic subdivisions of the striatum. Proc Natl Acad Sci USA 87:6912-6916.
22. Heffner TG, Zigmond MJ, Stricker EM (1977) Effects of dopaminergic agonists and antagonists on feeding in intact and 6-hydroxydopamine-treated rats. J Pharmacol Exp Ther 201:386-399.
23. Hervieu GJ, Cluderay JE, Harrison D, Meakin J, Maycox P, Nasir S, Leslie RA (2000) The distribution of the mRNA and protein products of the melanin-concentrating hormone (MCH) receptor gene, slc-1, in the central nervous system of the rat. Eur J Neurosci 12:1194-1216.
24. Hoebel BG, Hernandez L, Schwartz DH, Mark GP, Hunter GA (1989) Microdialysis studies of brain norepinephrine, serotonin, and dopamine release during ingestive behavior. Theoretical and clinical implications. Ann NY Acad Sci 575:171-191, 192-173.
25. 2 receptor contributions to ingestive and locomotor behavior are altered after dopamine depletions in neonatal rats. Neurosci Lett 118:120-123.
26. Jones SR, Gainetdinov RR, Wightman RM, Caron MG (1998) Mechanisms of amphetamine action revealed in mice lacking the dopamine transporter. J Neurosci 18:1979-1986.
27. Kelley AE, Berridge KC (2002) The neuroscience of natural rewards: relevance to addictive drugs. J Neurosci 22:3306-3311.
28. 2 receptors, and dopamine uptake sites in postmortem striatal specimens from schizophrenic patients. Biol Psychiatry 36:827-835.
29. 2 and re-uptake sites in rats with vacuous chewing movements. Brain Res 646:217-222.
30. Koob GF, Bloom FE (1988) Cellular and molecular mechanisms of drug dependence. Science 242:715-723.
31. Koob GF, Swerdlow NR (1988) The functional output of the mesolimbic dopamine system. Ann NY Acad Sci 537:216-227.
32. Koob GF, Stinus L, Le Moal M (1981) Hyperactivity and hypoactivity produced by lesions to the mesolimbic dopamine system. Behav Brain Res 3:341-359.
33. Korotkova TM, Sergeeva OA, Eriksson KS, Haas HL, Brown RE (2003) Excitation of ventral tegmental area dopaminergic and nondopaminergic neurons by orexins/hypocretins. J Neurosci 23:7-11.
34. Lucki I (1997) The forced swimming test as a model for core and component behavioral effects of antidepressant drugs. Behav Pharmacol 8:523-532.
35. Ludwig DS, Tritos NA, Mastaitis JW, Kulkarni R, Kokkotou E, Elmquist J, Lowell B, Flier JS, Maratos-Flier E (2001) Melanin-concentrating hormone overexpression in transgenic mice leads to obesity and insulin resistance. J Clin Invest 107:379-386.
36. Marsh DJ, Weingarth DT, Novi DE, Chen HY, Trumbauer ME, Chen AS, Guan XM, Jiang MM, Feng Y, Camacho RE, Shen Z, Frazier EG, Yu H, Metzger JM, Kuca SJ, Shearman LP, Gopal-Truter S, MacNeil DJ, Strack AM, MacIntyre DE, Van der Ploeg LH, Qian S (2002) Melanin-concentrating hormone 1 receptor-deficient mice are lean, hyperactive, and hyperphagic and have altered metabolism. Proc Natl Acad Sci USA 99:3240-3245.
37. Mogenson GJ, Nielsen MA (1983) Evidence that an accumbens to subpallidal GABAergic projection contributes to locomotor activity. Brain Res Bull 11:309-314.
38. 2 agonist quinpirole on exploratory locomotion. Brain Res 551:216-220.
39. Nahon JL (1994) The melanin-concentrating hormone: from the peptide to the gene. Crit Rev Neurobiol 8:221-262.
40. Perry KW, Fuller RW (1997) Fluoxetine increases norepinephrine release in rat hypothalamus as measured by tissue levels of MHPG-SO4 and microdialysis in conscious rats. J Neural Transm 104:953-966.
41. Pifl C, Agneter E, Drobny H, Sitte HH, Singer EA (1999) Amphetamine reverses or blocks the operation of the human noradrenaline transporter depending on its concentration: superfusion studies on transfected cells. Neuropharmacology 38:157-165.
42. Pitts SM, Horvitz JC (2000) Similar effects of D(1)/D(2) receptor blockade on feeding and locomotor behavior. Pharmacol Biochem Behav 65:433-438.
43. Qu D, Ludwig DS, Gammeltoft S, Piper M, Pelleymounter MA, Cullen MJ, Mathes WF, Przypek R, Kanarek R, Maratos-Flier E (1996) A role for melanin-concentrating hormone in the central regulation of feeding behaviour. Nature 380:243-247.
44. Ressler KJ, Nemeroff CB (2000) Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depress Anxiety 12 [Suppl 1]:2-19.
45. Rossi M, Choi SJ, O'Shea D, Miyoshi T, Ghatei MA, Bloom SR (1997) Melanin-concentrating hormone acutely stimulates feeding, but chronic administration has no effect on body weight. Endocrinology 138:351-355.
46. Rupniak NM, Carlson EC, Harrison T, Oates B, Seward E, Owen S, de Felipe C, Hunt S, Wheeldon A (2000) Pharmacological blockade or genetic deletion of substance P (NK(1)) receptors attenuates neonatal vocalisation in guinea-pigs and mice. Neuropharmacology 39:1413-1421.
47. Sailer AW, Sano H, Zeng Z, McDonald TP, Pan J, Pong SS, Feighner SD, Tan CP, Fukami T, Iwaasa H, Hreniuk DL, Morin NR, Sadowski SJ, Ito M, Bansal A, Ky B, Figueroa DJ, Jiang Q, Austin CP, MacNeil DJ, et al. (2001) Identification and characterization of a second melanin-concentrating hormone receptor, MCH-2R. Proc Natl Acad Sci USA 98:7564-7569.
48. Saito Y, Nothacker HP, Wang Z, Lin SH, Leslie F, Civelli O (1999) Molecular characterization of the melanin-concentrating-hormone receptor. Nature 400:265-269.
49. Saito Y, Cheng M, Leslie FM, Civelli O (2001) Expression of the melanin-concentrating hormone (MCH) receptor mRNA in the rat brain. J Comp Neurol 435:26-40.
50. Salamone JD, Zigmond MJ, Stricker EM (1990) Characterization of the impaired feeding behavior in rats given haloperidol or dopamine-depleting brain lesions. Neuroscience 39:17-24.
51. Saper CB, Chou TC, Elmquist JK (2002) The need to feed: homeostatic and hedonic control of eating. Neuron 36:199-211.
52. Shimada M, Tritos NA, Lowell BB, Flier JS, Maratos-Flier E (1998) Mice lacking melanin-concentrating hormone are hypophagic and lean. Nature 396:670-674.
53. Shippenberg TS, He M, Chefer V (1999) The use of microdialysis in the mouse: conventional versus quantitative techniques. Psychopharmacology (Berl) 147:33-34.
54. Shippenberg TS, Hen R, He M (2000) Region-specific enhancement of basal extracellular and cocaine-evoked dopamine levels following constitutive deletion of the Serotonin(1B) receptor. J Neurochem 75:258-265.
55. Smith AD, Olson RJ, Justice Jr JB (1992) Quantitative microdialysis of dopamine in the striatum: effect of circadian variation. J Neurosci Methods 44:33-41.
56. Szczypka MS, Kwok K, Brot MD, Marck BT, Matsumoto AM, Donahue BA, Palmiter RD (2001) Dopamine production in the caudate putamen restores feeding in dopamine-deficient mice. Neuron 30:819-828.
57. Takekawa S, Asami A, Ishihara Y, Terauchi J, Kato K, Shimomura Y, Mori M, Murakoshi H, Suzuki N, Nishimura O, Fujino M (2002) T-226296: a novel, orally active and selective melanin-concentrating hormone receptor antagonist. Eur J Pharmacol 438:129-135.
58. Tan CP, Sano H, Iwaasa H, Pan J, Sailer AW, Hreniuk DL, Feighner SD, Palyha OC, Pong SS, Figueroa DJ, Austin CP, Jiang MM, Yu H, Ito J, Ito M, Guan XM, MacNeil DJ, Kanatani A, Van der Ploeg LH, Howard AD (2002) Melanin-concentrating hormone receptor subtypes 1 and 2: species-specific gene expression. Genomics 79:785-792.
59. Wall SC, Gu H, Rudnick G (1995) Biogenic amine flux mediated by cloned transporters stably expressed in cultured cell lines: amphetamine specificity for inhibition and efflux. Mol Pharmacol 47:544-550.
60. Wang YM, Gainetdinov RR, Fumagalli F, Xu F, Jones SR, Bock CB, Miller GW, Wightman RM, Caron MG (1997) Knockout of the vesicular monoamine transporter 2 gene results in neonatal death and supersensitivity to cocaine and amphetamine. Neuron 19:1285-1296.
61. Wise RA, Bozarth MA (1985) Brain mechanisms of drug reward and euphoria. Psychiatr Med 3:445-460.
62. Wu M, Brudzynski SM, Mogenson GJ (1993) Differential effects of quinpi-role in the nucleus accumbens depending on the initial level of locomotor activity. Brain Res Bull 32:395-398.
63. 1 receptor mutant mice. Cell 79:945-955.
64. 1 receptor mutant mice are deficient in striatal expression of dynorphin and in dopamine-mediated behavioral responses. Cell 79:729-742.
65. 1 receptor. Brain Res 852:198-207.
66. Yamamoto BK, Novotney S (1998) Regulation of extracellular dopamine by the norepinephrine transporter. J Neurochem 71:274-280.
67. 2 receptor: role of dopamine in presynaptic inhibition. J Neurosci 6:2470-2478.
68. Zocchi A, Girlanda E, Varnier G, Sartori I, Zanetti L, Wildish GA, Lennon M, Mugnaini M, Heidbreder CA (2003) Dopamine responsiveness to drugs of abuse: a shell-core investigation in the nucleus accumbens of the mouse. Synapse 50:293-302.